195 related articles for article (PubMed ID: 25753245)
1. High-sensitivity C-reactive protein does not improve the differential diagnosis of HNF1A-MODY and familial young-onset type 2 diabetes: A grey zone analysis.
Bellanné-Chantelot C; Coste J; Ciangura C; Fonfrède M; Saint-Martin C; Bouché C; Sonnet E; Valéro R; Lévy DJ; Dubois-Laforgue D; Timsit J;
Diabetes Metab; 2016 Feb; 42(1):33-7. PubMed ID: 25753245
[TBL] [Abstract][Full Text] [Related]
2. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
[TBL] [Abstract][Full Text] [Related]
3. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
[TBL] [Abstract][Full Text] [Related]
4. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
Juszczak A; Pavić T; Vučković F; Bennett AJ; Shah N; Pape Medvidović E; Groves CJ; Šekerija M; Chandler K; Burrows C; Rojnić Putarek N; Vučić Lovrenčić M; Ćuća Knežević J; James TJ; Gloyn AL; Lauc G; McCarthy MI; Owen KR; Gornik O
Diabetes Care; 2019 Jan; 42(1):17-26. PubMed ID: 30455330
[TBL] [Abstract][Full Text] [Related]
5. New clinical screening strategy to distinguish
Ma Y; Gong S; Wang X; Cai X; Xiao X; Gu W; Yang J; Zhong L; Xiao J; Li M; Liu W; Zhang S; Zhou X; Li Y; Zhou L; Zhu Y; Luo Y; Ren Q; Huang X; Gao X; Zhang X; Zhang R; Chen L; Wang F; Wang Q; Hu M; Han X; Ji L
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32238361
[TBL] [Abstract][Full Text] [Related]
6. An alternative approach using hs-CRP levels and age of onset in diagnostics of HNF1A-MODY.
Kickova T; Skopkova M; Dobiasova Z; Lackova G; Belicova Z; Schenkova K; Stanik J; Gasperikova D
Diabet Med; 2024 May; 41(5):e15265. PubMed ID: 38093550
[TBL] [Abstract][Full Text] [Related]
7. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes.
Thanabalasingham G; Shah N; Vaxillaire M; Hansen T; Tuomi T; Gašperíková D; Szopa M; Tjora E; James TJ; Kokko P; Loiseleur F; Andersson E; Gaget S; Isomaa B; Nowak N; Raeder H; Stanik J; Njolstad PR; Malecki MT; Klimes I; Groop L; Pedersen O; Froguel P; McCarthy MI; Gloyn AL; Owen KR
Diabetologia; 2011 Nov; 54(11):2801-10. PubMed ID: 21814873
[TBL] [Abstract][Full Text] [Related]
8. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.
Besser RE; Shepherd MH; McDonald TJ; Shields BM; Knight BA; Ellard S; Hattersley AT
Diabetes Care; 2011 Feb; 34(2):286-91. PubMed ID: 21270186
[TBL] [Abstract][Full Text] [Related]
9. Traditional clinical criteria outperform high-sensitivity C-reactive protein for the screening of hepatic nuclear factor 1 alpha maturity-onset diabetes of the young among young Asians with diabetes.
Rama Chandran S; Bhalshankar J; Farhad Vasanwala R; Zhao Y; Owen KR; Su-Lyn Gardner D
Ther Adv Endocrinol Metab; 2018 Sep; 9(9):271-282. PubMed ID: 30181854
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene.
Bellanné-Chantelot C; Lévy DJ; Carette C; Saint-Martin C; Riveline JP; Larger E; Valéro R; Gautier JF; Reznik Y; Sola A; Hartemann A; Laboureau-Soares S; Laloi-Michelin M; Lecomte P; Chaillous L; Dubois-Laforgue D; Timsit J;
J Clin Endocrinol Metab; 2011 Aug; 96(8):E1346-51. PubMed ID: 21677039
[TBL] [Abstract][Full Text] [Related]
12. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
[TBL] [Abstract][Full Text] [Related]
13. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
[TBL] [Abstract][Full Text] [Related]
14. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
Liu J; Xiao X; Zhang Q; Yu M
J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
[TBL] [Abstract][Full Text] [Related]
17. Maturity onset diabetes of the young due to
Pavić T; Juszczak A; Pape Medvidović E; Burrows C; Šekerija M; Bennett AJ; Ćuća Knežević J; Gloyn AL; Lauc G; McCarthy MI; Gornik O; Owen KR
Biochem Med (Zagreb); 2018 Jun; 28(2):020703. PubMed ID: 29666556
[TBL] [Abstract][Full Text] [Related]
18. Can Biomarkers Help Target Maturity-Onset Diabetes of the Young Genetic Testing in Antibody-Negative Diabetes?
Majidi S; Fouts A; Pyle L; Chambers C; Armstrong T; Wang Z; Batish SD; Klingensmith G; Steck AK
Diabetes Technol Ther; 2018 Feb; 20(2):106-112. PubMed ID: 29355436
[TBL] [Abstract][Full Text] [Related]
19. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
[TBL] [Abstract][Full Text] [Related]
20. RD Lawrence lecture 2012: assessing aetiology in diabetes: how C-peptide, CRP and fucosylation came to the party!
Owen KR
Diabet Med; 2013 Mar; 30(3):260-6. PubMed ID: 23106207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
